PLx Pharma Winddown Corp.
PLXPQ
OTC PK
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Revenue | -31.32% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -100.74% |
| Total Revenue | -31.32% | 2,693,575.00% | 37,321.45% | 27,259.67% | 12,083.43% |
| Cost of Revenue | 10.95% | -- | -- | -- | -- |
| Gross Profit | -92.50% | 995,000.00% | 15,596.73% | 11,242.00% | 4,877.16% |
| SG&A Expenses | 187.32% | 408.43% | 500.80% | 337.28% | 126.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 128.03% | 337.74% | 366.60% | 263.24% | 122.74% |
| Operating Income | -172.64% | -274.19% | -294.26% | -203.07% | -74.72% |
| Income Before Tax | 52.18% | -4.01% | -60.62% | -203.23% | -524.83% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 52.18% | -4.01% | -60.62% | -203.23% | -524.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 52.18% | -4.01% | -60.62% | -203.23% | -524.83% |
| EBIT | -172.64% | -274.19% | -294.26% | -203.07% | -74.72% |
| EBITDA | -173.44% | -276.06% | -296.80% | -205.04% | -75.56% |
| EPS Basic | 69.09% | 46.36% | 29.92% | -18.45% | -159.79% |
| Normalized Basic EPS | 67.40% | 41.77% | 28.84% | -28.99% | -200.33% |
| EPS Diluted | 69.12% | 46.50% | 30.12% | -17.98% | -158.32% |
| Normalized Diluted EPS | 67.40% | 41.77% | 28.84% | -28.91% | -200.05% |
| Average Basic Shares Outstanding | 45.34% | 86.30% | 137.94% | 153.99% | 109.37% |
| Average Diluted Shares Outstanding | 45.34% | 86.30% | 137.94% | 153.58% | 109.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |